← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	1,969	-1	-0.1%	$136B
2	2 Amgen AMGN $235B	1,436	-19	-1%	$90.4B
3	3 Eli Lilly LLY $1.12T	1,152	-69	-6%	$60B
4	4 Becton Dickinson BDX $52.8B	958	-8	-0.8%	$26.9B
5	5 McKesson MCK $117B	937	-37	-4%	$30B
6	6 Teva Pharmaceutical Industries Limited TEVA $47.9B	837	-40	-5%	$32.1B
7	7 Conagra Brands CAG $6.77B	671	+15	+2%	$14.9B
8	8 Regeneron Pharmaceuticals REGN $82B	550	-27	-5%	$26.2B
9	9 Novo Nordisk NVO $173B	536	-13	-2%	$10.7B
10	10 DaVita DVA $12.1B	475	-28	-6%	$12.9B
11	11 AstraZeneca AZN $258B	390	0	0%	$7.26B
12	12 ResMed RMD $34.1B	375	+23	+7%	$4.83B
13	13 Accendra Health ACH $20.1M	286	+16	+6%	$2.54B
14	14 Opko Health OPK $1.2B	259	-14	-5%	$1.19B
15	15 West Pharmaceutical WST $27B	251	+2	+0.8%	$4.75B
16	16 Herbalife HLF $1.53B	227	+14	+7%	$6.22B
17	17 DELISTED CATALENT, INC. CTLT	174	-14	-7%	$3.37B
18	18 Fresenius Medical Care FMS $11.8B	173	+25	+17%	$608M
19	19 Tootsie Roll Industries TR $2.88B	171	0	0%	$492M
20	20 Dr. Reddy's Laboratories RDY $10.8B	160	-14	-8%	$1.24B
21	21 MannKind Corp MNKD $1.03B	153	-20	-12%	$150M
22	22 DELISTED WW International WW	149	+5	+3%	$849M
23	23 Alaunos Therapeutics TCRT $5.46M	143	-13	-8%	$416M
24	24 Medifast MED $135M	133	+2	+2%	$314M
25	25 Lexicon Pharmaceuticals LXRX $734M	132	+14	+12%	$1.32B